Molecular Characterization of Respiratory Syncytial Virus Infections in Elderly Patients During the 2023-2024 Season in the Era of Nirsevimab Introduction.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39895281.
- Also identified by DOI 10.1093/infdis/jiaf062.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Respiratory syncytial virus (RSV) can cause severe infections in elderly individuals. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023-2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly. In this study, we analyzed RSV full-length genomes (68% RSV-A, 32% RSV-B) from 125 patients aged >60 years during the 2023-2024 season. Genetic diversity of RSV-F site Ø was low, with no resistance-associated substitutions (RASs) detected. While no RASs were identified, ongoing monitoring is essential to prevent the emergence of resistant variants that could affect vaccine efficacy in the elderly.
Medical subject headings
- Respiratory Syncytial Virus Infections
- Respiratory Syncytial Virus, Human
- Antibodies, Monoclonal, Humanized
- Antiviral Agents